Advanced Solutions
for Advanced Pathology
CD44 (MRQ-13)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45184 IMPATH CD44 RTU M (MRQ-13)
50 Tests
44240 CD44 RTU M (MRQ-13)
7 ml Ready To Use
44502 CD44 0,1 M (MRQ-13)
100 µl liquid Concentrated
44503 CD44 1 M (MRQ-13)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Membranous
Control
Benign Urothelium
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
2a
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Enzyme 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP 2-step Polymer (Universal) or AP
2-step Polymer (Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
The CD44 family of glycoproteins exists in a number of variant isoforms, the most common being the standard 85-95 kD or hematopoietic variant
(CD44s) that is found in mesodermal cells such as hematopoietic, fibroblastic, and glial cells, as well as in some carcinoma cell lines. Higher
molecular weight isoforms have been described in epithelial cells (CD44v) and are thought to function in intercellular adhesion and stromal
binding. While many human tumors express CD44, a positive correlation between increased CD44v expression and tumor progression and/or
dedifferentiation has been demonstrated in only some. Probably the most practical application of anti-CD44 immunostaining at present is the
discrimination of urothelial transitional cell carcinoma in-situ from non-neoplastic changes in the urothelium.
Bladder: Dysplasia vs. Reactive
CD44
CK 20
p53
Ki-67
Carcinoma in-situ
-
+
+
+
Reactive Atypia
+(all cell layers)
-
-
+
Normal Urothelium
+(umbrella cells)
+(umbrella cells)
-
-
Reference
1. Abbasi AM, et al. Eurpoean Journal of Cancer. 1993; 29A:294.
2. Chuang CK, Liao SK. Anticancer Res. 2003 Nov-Dec; 23(6C):4635-9.
3. East JE, Hart IR. European Journal of Cancer. 1993; 29A:1921-22.
4. Ekici S, et al. Journal of Urology. 2002; 167:2037-41.
5. Gadalla HA, et al. BJU Int. 2004 Jan; 93(1):151-5.
69
